ritonavir and delanzomib

To investigate the efficacy against renal cancer cells of combining the HIV protease inhibitor ritonavir with the novel proteasome inhibitor delanzomib.. Renal cancer cell lines 769-P, 786-O, Caki-2 and Renca were treated with ritonavir and delanzomib in vitro and in vivo, and the efficacy of combination was evaluated.. The combination of ritonavir and delanzomib synergistically inhibited renal cancer growth and suppressed colony formation. It induced robust apoptosis evidenced by increased cell population in the sub-G. The effectiveness of combination of ritonavir and delanzomib appears to be due to the induction of ER stress and inhibition of the mTOR pathway.

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Carcinoma, Renal Cell; Cell Line, Tumor; Cytochrome P-450 CYP3A Inhibitors; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Proteasome Inhibitors; Ritonavir; Threonine